Angiotensin Receptor Neprilysin Inhibitor [ARNI] and Its Implications Ejection Fraction Preserved Heart Failure: A Recent Review

Alokita Trivedi a#*, Ajinkya Punpale a#, Swarali Kale a# and Sunil Kumar b≡

a Jawaharlal Nehru Medical College, Datta Megha Institute of Medical Sciences (Deemed to be University), Wardha, India.
b Department of Medicine, Jawaharlal Nehru Medical College, Datta Meghe Institute of Medical Sciences (Deemed to be University), Wardha, India.

Authors’ contributions
This work was carried out in collaboration among all authors. All authors read and approved the final manuscript.

Article Information
DOI: 10.9734/JPRI/2021/v33i60b34728

Open Peer Review History:
This journal follows the Advanced Open Peer Review policy. Identity of the Reviewers, Editor(s) and additional Reviewers, peer review comments, different versions of the manuscript, comments of the editors, etc are available here: https://www.sdiarticle5.com/review-history/79613

Received 15 October 2021
Accepted 20 December 2021
Published 23 December 2021

ABSTRACT
This review article discusses the Angiotensin Receptor-Neprilysin Inhibitor which is remedy made up of two anti-hypertensive pharmaceuticals (sacubitril and valsartan). These medications may prolong life expectancy more than ACE inhibitors, which have been routinely used to treat heart failure. ARNi is now being used to treat individuals with heart failure those who have a low ejection fraction, which means their basic pumping chamber isn't working properly. Patients must be symptomatic despite receiving effective medical treatment for heart failure or be unable to tolerate a sufficient dose of ACE inhibitors to be eligible. Sacubitril and/or Valsartan are the debut members of a latest class of drugs described as angiotensin receptor neprilysin inhibitors to receive FDA approval (ARNI). The FDA has approved the medicine for the management of chronic heart failure sufferers with a lower ejection fraction and NYHA classifications II, III, or IV. Before commencing sacubitril and/or valsartan, patients must have to be able to accommodate ACEI or ARB. This intervention covers the instances, mode of action, approaches of administration,
significant toxic reactions, risks and benefits, bioactivity, and surveilling of sacubitril & valsartan so as to the practitioners can control patients under therapy in settings into which it implies as a part of the effective interprofessional.

Keywords: ARNI; heart failure; ejection fraction.

1. INTRODUCTION

The Angiotensin Receptor-Neprilysin Inhibitor (ARNI) is a blood pressure-lowering medication made up of two antihypertensive medicines Sacubitril and Valsartan. Valsartan affects the activity of a kidney hormone called angiotensin II by inhibiting the receptors to which it normally attaches, which can be harmful in those with heart failure. This mechanism lowers the hormone’s toxic effects on the heart and allows vasodilatation or broaden. Sacubitril prevents the body’s natriuretic peptides from being broken down. Sodium and water are excreted in the urine via natriuretic peptides. This impact lowers blood pressure and reduces work on the heart.

Heart failure is a widespread concern that affects well over 26 million people. Heart failure is much more evident over the world, and it is presumed to become so as the world’s population ages. Low ejection fraction heart failure directly influences around half of all heart failure sufferers in The United States, and it’s closely linked with a lot of comorbidities and low quality of life [1].

2. MAIN APPROACH

Notwithstanding from long-established angiotensin-converting enzyme inhibitors and angiotensin receptor blockers, three of the drug classes (mineralocorticoid receptor antagonists, angiotensin receptor-neprilysin inhibitors & sodium/glucose cotransporter 2 inhibitors) has also been exhibited to improve findings in heart failure in adults with a low ejection fraction. Since every class has been properly assessed separately with different and unique drugs, the possible therapy benefits of combining them have not been determined. They looked at data from three original research randomised controlled trials to see how often patients with chronic HFREF who got comprehensive therapy had satisfactory continued existence and clinical outcome than those who received conventional therapy [2].

Reduced ejection fraction heart failure solution:-

Both the Dapagliflozin and Empagliflozin trials demonstrated that the blocking SGLT2 help in decreasing the overall risk of cardiovascular fatalities or hospitalisation in patients with HFREF and diabetes. Anyway, neither study was large enough to evaluate effects on heart or all-cause mortality or else to signalise outcomes in the practically meaningful subgroups. Manipulating study-level printed data from DAPA-HF and patient-level information from the EMPEROR-Reduced trials, we aimed to see how SGLT2 inhibition affected fatal as well as non-fatal heart failure events as well as renaissance [3].

Adults with longterm heart failure (HF) were nonetheless at a higher danger of consequences, despite major therapeutic advancements. Sacubitril valsartan is a new oral medicine that has been proven to help diagnosable chronic heart failure in sick people with a poor ejection fraction. Because it combines sacubitril, a neprilysin inhibitor, and valsartan, an angiotensin II receptor antagonist, its known the first in class (ARNI). Neprilysin is an endopeptidase which also digests natriuretic peptides (NPs), bradykinin, endothelin, and angiotensin II, among other vasoactive peptides (Ang-II). As a consequence, the inhibition of NPs and Ang-II causes a rise in plasmatic levels of both (with opposite biological actions). Although the Ang-II receptor is inhibited, a mixture of inhibitors of these two systems (Sacubitril / valsartan) may enhance the benefits of NPs in HF (natriuresis, diuresis, etc). In a large clinical trial, this innovational medicine was found to appreciably lower cardio respiratory and other causatory fatalities, and as well hospitalization owing to HF. This paper discusses sacubitril valsartan's clinical data, dose and precautionary measures, possible trends, and prospective involvement in correction of HF with decreased ejection fraction [4].

The impacts of the empagliflozin and the dapagliflozin on the heart failure hospitalization remained similar into both investigations, indicating that these medications may strengthen renal results and decrease cumulative and
cardiovascular deaths in individuals with reduced ejection fraction [4].

PARAGON HF Trial:-

The PARAGON HF trial is perhaps the multi-center, double-blind study that compares likelihood of the heart failure hospital treatment and cardiology related death in the patients with HFpEF medicated with the sacubitril/valsartan (Entresto®) comparison to valsartan only in sufferers with the HFpEF. Individuals with the HFpEF who have lately been admitted are more likely to experience diagnostic and therapeutic trajectory in the near future. According to the PARAGON-HF research, the absolute and relative merits of sacubitril/valsartan over valsartan in HFpEF appear to be increased when begun in the high-risk window after hospitalisation, and they warrant prospective verification. Renal function is typically decreased in individuals with heart failure and decreased ejection fraction, also it may worsen after renin-angiotensin system blockage. According to preliminary findings, ARNI therapy resulted in considerable reversal of harmful cardiac remodelling [5].

Reverse Cardiac Modelling:-

EVALUATE-HF give more solid evidence on the influence of ARNI medication on redesigning measures.(Study of effects of sacubitril & valsartan v/s enalapril on aortic stiffness in patients with mild to moderate heart failure) [6].

In the world's care delivery, cardiovascular diseases (CVDs) remain the major cause of mortality and disabilities. Despite massive shots over the last 20 years to reduce occurrence of CVS events, their prevalence is on the ascent, and regulation remains unsatisfactory. As an outcome, it's vital to have innovative therapeutic alternatives that engage with diverse pathophysiological systems to avoid the emergence of clinical CVDs. Neurohormonal system like the RAAS system and sympathetic nervous system have been found to be beneficial in treating a wide variety of CVDs in the past. Targeting alternative hormonal mechanism, natriuretic peptides , that can also influence the development of CVDs when downregulated, has recently been attempted. ARNi are a latest type of medicine which can reduce angiotensin II's impacts while also increasing NP functioning [7].

Ventricular Arrhythmias and ARNI:-

ARNi which has been shown to help those individuals with heart failure those have a decreased ejection fraction. As per new findings, ARNI use should expand in the next years to add on other CVDs like heart failure with an unchanged EF and high blood pressure [8].

The probability of the sudden cardiac death (SCD) in people with the heart failure (HF) and a decreased ejection fraction (HFrEF) has been cut in half because to incredible new technologies. SCD, on the other hand, persists to constitute among one of leading triggers of fatalities in this kind of patient population. A novel family of medications known as ARNI, has been discovered to lower aggregate cardiovascular illness and death and, more particularly, coronary heart disease fatalities, in addition to the documented benefits of the beta blockers and RAAS inhibitors. The mechanism through which ARNI may lower mortality caused by dangerous ventricular arrhythmias is unknown. A variety of two pathways have been hypothesised, but advantageous left ventricular flip reworking does seem to play a critical influence in this situation. In addition, the prominent protective potency of a biocompatible cardioverter-defibrillator (ICD) in reduced ejection fraction patients with the non-ischemic cardiomyopathy (NICM) has been called into question, with several asserting against the use of a prevention strategies ICD in this situation, especially when ARNI intervention is taken into account [8].

Sacubitril/valsartan (LCZ696) was observed to be higher to an ARB individually in lowering central aortic systolic pressure (primary goal), centralized aortic pulse tension (secondary endpoint), and nightly blood pressure (BP). Provided these study aggregations, sacubitril/valsartan might be appropriate health-giving choice for older adults with age-relevant hypertension phenotypes . Those are strong hypertension morphologies, who are more prone to build up heart failure and advanced kidney illness as a result of their EF remaining constant. Sacubitril/valsartan may be beneficial for not just the secondary prophylaxis, but also for health promotion of heart failure in old aged hypertension patients who are uncontrollable [9].

ARNI- When to use, how to use and on whom to use:-

The conjunction of angiotensin II receptor antagonist & neprilysin inhibitor (ARNI) is a
newbie in treating heart failure with diminished left sided ventricular ejection fraction (LVEF). In PARADIGM-HF research, sacubitril & valsartan was found to have been more effective than to enalapril in decreasing cardiovascular deaths and fatalities and heart failure hospital admissions in outpatient clinics with an LVEF of 35-40%. The current study discusses the precautions to take before starting sacubitril-valsartan, as well as its use and place in the pharmacological management strategy for chronic heart failure. Additional information on individuals with low LVEF, patients with LVEF > 45 percent, and the impact on blood pressure, renal, and cognitive functions is offered [10].

ARNI v/s ACEI:-

To interpret the base - line traits and therapies of patients chosen randomly in PARADIGM-HF trial, with mission of validating that blocking the RAAS system while accelerating natriuretic peptides with LCZ696 200 mg b.i.d. is far better than the current standard of care.

In the PARADIGM-HF survey, ARNI was reported to be able to reduce the risk of fatalities from cardiovascular ailments or hospitalisation for heart failure. It also lowers the risk of overall mortality and enhanced physical function in people with heart failure [11].

Sacubitril with Valsartan in Treatment of the Heart Failure:-

Sacubitril and valsartan are 1st angiotensin receptor-neprilysin inhibitor (ARNI) which have been recommended in the assessment and treatment of patient populations with chronic, symptomatic HF with a lower ejection fraction to lessen illness and death (HFrEF). This study gives an explanation of ARNI therapy, recommends options to strengthen sacubitril/valsartan execution in patient care, and gives doctors substantial proof, practical advice on sacubitril/valsartan use in HFrEF patients. Considering evidentiary that ARNI therapy provides benefits placed above a standard care, sacubitril/valsartan is only used by a tiny fraction of eligible individuals. Unawareness of ARNIs among consultants, perceived risks, and payment issues from payers may be impediments to dispensing sacubitril/valsartan to appropriate patients. When used effectively in treatment planning, sacubitril/valsartan has the potential to reduce the cumulative hardship of HF. In this review, we discuss our experiences with sacubitril/valsartan, including how to manage bad effects and frequently reported patient considerations. A management array technique for the incorporation of sacubitril/valsartan is also given [12].

Preference of ARNI over ARBs in Cardiovascular control:-

High blood pressure, diabetes, and nephropathy are all linked to an upsurge in cardiovascular and renal comorbidities and fatalities. In such high-risk, multi-morbid subgroups of patients, antihypertensive treatment is not very effective. By boosting the intrinsic counterpoint of the natriuretic peptide system, synchronous angiotensin II-type 1 receptors blockage and neprilysin inhibition with valsartan or sacubitril - (LCZ696) may cause a buildup of renin-angiotensin-aldosterone inhibition.In this review, the outcomes of this approach on living creatures are explored. In cardiovascular disease risk animal models of high blood pressure, ARNI greatly reduced heart burden and cardiovascular fibrosis, regardless alone or in combined application with myocardial infarction or diabetes. In addition, LCZ696 treatment lower overall protein in urine, retinopathy and focal segmental glomerulosclerosis, implying that it has microvascular benefits as well. These outcomes and results were confirmed in patient groups. In diabetic individuals, ventricular wall pressures and albuminuria have been scaled down, in addition to decreasing blood pressure in hypertensive individuals and fairly low (cardiovascular) fatalities in sufferers with heart failure. The exact mechanism is unknown, but nevertheless it can maybe incorporate better overall renal haemodynamics and reduced glomerulosclerosis, which can also be attributed to an increase in natriuretic peptide levels. The tests of certain peptides, however, were impeded by research methodology artworks. Besides which, considering sacubitril is largely excreted via the kidneys, medicine accumulation might ensue in patient populations with defective nephrro functionality, potentially leading to hypotension in those with chronic kidney disease. Neprilysin degrades amyloid beta & endothelin-1 in experimental models, and thus utmost care is urged. The latter's accumulation may raise the chance of Alzheimer's disease [13].
Positive effects of Sacubitril and Valsartan on the glycemic control:

Diabetes mellitus (DM) is correspondent in individuals with (HF), with a preponderance of 35-40% in sufferers with HF, notwithstanding the degree of ejection fraction impairment (EF). Addition, diabetes mellitus (DM) is associated with a terrible prognosis and is cogitate about a major unbiased pit fall for progression of HF with either managed or shortened ejection fraction. Nepriylsen inhibitors also were recommended as a legitimate therapies for HF due to their ability to boost scores of biologically active compounds natriuretic peptides. In PARADIGM-HF trial, sacubitril/valsartan, the dual-acting ARNI, had already been proven to be extremely useful than enalapril in shrinking the hazards of fatal injury and HF hospital visits in individuals ith HF with lesser EF. Also in addition, a post-hoc analyses of the following study indicated that sacubitril/valsartan medication positively affected glycemic control in those with diabetes particularly in comparison to enalapril. Furthermore, new study reveals that this class of drugs has beneficial physiologic effects. This review goes through the effects of sacubitril and valsartan on glycemic control in great depth. Sacubitril and valsartan limits nepriylsen by blocking the renin-angiotensin system. Nepriylsen silencing may improve glycemic control in a range of ways, with the preponderance of evidence attempting to point to changes in propagating nepriylsen substrates. Despite there is some notion that blocking the renin-angiotensin system boosts glucose metabolism, it is far more likely a minimal benefit. To better comprehend sacubitril/favorable valsartan's metabolic properties, additional detailed metabolic prosecutions, and also some large randomised preclinical studies in diabetes sufferers, are warranted [14].

Combination of Angiotensin II receptor 1 antagonism with the Nepriylsen inhibition for treatment of heart failure:

Sacubitril and valsartan is first-of-its-kind remedy which somehow merges a nepriylsen inhibitor and an angiotensin receptor blocker in a single supplement. Sacubitril prevents natriuretic peptides (NP) from being degraded by blocking nepriylsen endopeptidase, hence incrementing their bioavailability. Valsartan blocks spike in angiotensin II generated by nepriylsen inhibition, as well as the advantageous out-turns of angiotensin receptor blockers eyed in the previous HF trials. Sacubitril - valsartan (LCZ696) is better in comparison to ACE inhibitor enalapril in lowering fatalities and comorbidities in bothersome HF patients with lessened ejection fraction in the PARADIGM-HF study, opening the path for sacubitril/valsartan to swap ACE inhibitors in treating of reduced ejection fraction. Sacubitril and valsartan is under testing in phase III trials (PARAGON-HF) in people suffering from HF with maintained EF. PARAGON-HF will also yield more insights on the protection of sacubitril/long-term valsartan, alleviating concerns about the influence of nepriylsen inhibition on cognitive performance [15-20].

3. CONCLUSION

Sacubitril and valsartan, the two active compounds, work in various ways. Valsartan affects the activity of a renal hormone called angiotensin II by obstructing the receptors to that which conventionally interacts, which can be harmful in those with heart failure. This impact lessens the hormone's harmful consequence on the heart and allows blood vessels to inflate or broaden.

Sacubitril prevents body's natriuretic peptides from being broken down. Sodium and water are excreted in the urine via natriuretic peptides. This impact lowers blood pressure and reduces work on the heart. The two drugs work together to relieve the load on the weakening heart.

Sacubitril/valsartan has been found to decrease heart failure hospitalizations and enhance survival.

The ARNI treatment is quite well observed. Angioedema, a strong allergic reaction, is the most serious but exceedingly rare possible consequence of sacubitril/valsartan. Sacubitril/valsartan should be used in heart failure patients who are already exhibiting signs while consuming an ACE inhibitor at maximum dose. It should not be used by service users who are also on ACE inhibitors or ARBs.

DISCLAIMER

The products used for this research are commonly and predominantly use products in our area of research and country. There is absolutely no conflict of interest between the authors and producers of the products because we do not intend to use these products as an avenue for any litigation but for the advancement of
knowledge. Also, the research was not funded by the producing company rather it was funded by personal efforts of the authors.

**CONSENT**

It is not applicable.

**ETHICAL APPROVAL**

It is not applicable.

**COMPETING INTERESTS**

Authors have declared that no competing interests exist.

**REFERENCES**

1. Bloom MW, Greenberg B, Jaarsma T, Januzzi JL, Lam CSP, Maggioni AP, et al. Heart failure with reduced ejection fraction. Nat Rev Dis Primers. 2017;3:17058.

2. Vaduganathan M, Claggett BL, Jhund PS, Cunningham JW, Pedro Ferreira J, Zannad F, et al. Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials. Lancet. 2020;396(10244):121-128.

3. Zannad F, Ferreira JP, Pocock SJ, Anker SD, Butler J, Filippatos G, et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet. 2020;396(10254):819-829.

4. Kaplinsky E. Changing the treatment of heart failure with reduced ejection fraction: Clinical use of sacubitril-valsartan combination. J Geriatr Cardiol. 2016;13(11):914-923.

5. Tridetti J, Nguyen Trung ML, Ancion A, Lancellotti P. L’étude clinique du mois. PARAGON-HF : sacubitril/valsartan (Entresto®) dans l’insuffisance cardiaque à fraction d’éjection préservée (HFpEF) [The PARAGON-HF trial]. Rev Med Liege. French. 2020;75(2):130-135.

6. Tridetti J, Nguyen Trung ML, Ancion A, Lancellotti P. L’étude clinique du mois. PARAGON-HF: sacubitril/valsartan (Entresto®) dans l’insuffisance cardiaque à fraction d’éjection préservée (HFpEF) [The PARAGON-HF trial]. Rev Med Liege. French. 2020;75(2):130-135.

7. Tridetti J, Nguyen Trung ML, Ancion A, Lancellotti P. L’étude clinique du mois. PARAGON-HF: sacubitril/valsartan (Entresto®) dans l’insuffisance cardiaque à fraction d’éjection préservée (HFpEF) [The PARAGON-HF trial]. Rev Med Liege. French. 2020;75(2):130-135.

8. Vecchi AL, Abete R, Marazzato J, Iacovoni A, Mortara A, De Ponti R, Senni M. Ventricular arrhythmias and ARNI: Is it time to reappraise their management in the light of new evidence? Heart Fail Rev; 2020.

9. Kario K. The sacubitril/valsartan, a first-in-class, angiotensin receptor neprilysin inhibitor (ARNI): Potential uses in hypertension, Heart Failure, and Beyond. Curr Cardiol Rep. 2018;20(1):5.

10. Russo-Vorms L, Meyer P, Reny JL. « ARNI » (Angiotensin Receptor-Neprilysin Inhibitor) : quand, pour qui et comment ? [« ARNI » (Angiotensin Receptor-Neprilysin Inhibitor): When, for whom and how?]. Rev Med Suisse. French. 2019;15(667):1882-1886.

11. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz M, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR; PARADIGM-HF Committees Investigators. Baseline characteristics and treatment of patients in prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF). Eur J Heart Fail. 2014;16(7):817-25.

12. Sauer AJ, Cole R, Jensen BC, Pal J, Sharma N, Yehya A, Vader J. Practical guidance on the use of sacubitril/valsartan for heart failure. Heart Fail Rev. 2019;24(2):167-176.

13. Uijl E, Roksnoer LC, Hoom EJ, Danser AH. From ARB to ARNI in Cardiovascular Control. Curr Hypertens Rep. 2016;18(12):86. DOI: 10.1007/s11906-016-0694-x. Kristensen SL, Preiss D, Jhund PS, Squire I, Cardoso JS, Merkely B, etal. PARADIGM-HF investigators and committees. Risk Related to Pre-Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction: Insights From Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure.
1173 Failure Trial. Circ Heart Fail. 2016; 9(1):e002560.
14. Seferovic JP, Solomon SD, Seely EW. Potential mechanisms of beneficial effect of sacubitril/valsartan on glycemic control. Ther Adv Endocrinol Metab. 2020; 11:2042018820970444.
15. Katsanos S, Bistola V, Parissis JT. Combining angiotensin II receptor 1 antagonism and neprilysin inhibition for the treatment of heart failure. Expert Rev Clin Pharmacol. 2016;9(4):513-523.
16. Andhale Amol, Sourya Acharya, Shree Karthik Pratapa, Vidyashree Hulkoti. An unusual case of acute heart failure in a body builder: Case report. MEDICAL SCIENCE. 2020;24(103):1744–48.
17. Anjankar Ashish Prakash, Sandip Deepak Lambe, Kanchan Sandip Lambe. Diagnostic and prognostic value of N-terminal brain natriuretic peptide in patients of heart failure. Journal of Evolution of Medical and Dental Sciences-JEMDS. 2020;9(31):2176–80.
18. Available:https://doi.org/10.14260/jemds/2020/474.
19. Abafati Cristiana, Kaja M Abbas, Mohammad Abbasi, Mitra Abbasifard, Mohsen Abbasi-Kangevari, Hedayat Abbastabar, Foad Abd-Allah, et al. Five insights from the global burden of disease study 2019. LANCET. 2020; 396(10258):1135–59.
20. Abafati Cristiana, Kaja M Abbas, Mohammad Abbasi, Mitra Abbasifard, Mohsen Abbasi-Kangevari, Hedayat Abbastabar, Foad Abd-Allah, et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: A systematic analysis for the global burden of disease study 2019. LANCET. 2020; 396(10258):1204–22.

© 2021 Trivedi et al.; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peer-review history:
The peer review history for this paper can be accessed here: https://www.sdiarticle5.com/review-history/79613